BIG
ELVN icon

Brooklyn Investment Group’s Enliven Therapeutics ELVN Stock Holding History

Brooklyn Investment Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$457K Buy
+11,660
New +$323K 0.01% 1097

Other funds holding ELVN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Brooklyn Investment Group's ELVN Position: Q1 2026 in Review

Brooklyn Investment Group opened a new position in Enliven Therapeutics (ELVN) in Q1 2026: 11,660 shares worth $457K. The stake represents 0.01% of the portfolio and ranks #1097 among its holdings.

170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Brooklyn Investment Group held 11,660 shares of Enliven Therapeutics worth $457K as of Q1 2026.
  • Enliven Therapeutics was a new Brooklyn Investment Group position in Q1 2026.
  • Enliven Therapeutics made up 0.01% of Brooklyn Investment Group's portfolio in Q1 2026, its #1097 holding.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.